Dr. Eric Rowinsky is a consultant to CANCER PANELS. He is an adjunct Professor of Medicine, Division of Medical Oncology, at the New York University School of Medicine. Since 2008, Dr. Rowinsky has been consultant to Champions Oncology, Inc. From 2005 to 2009, he served as the Chief Medical Officer of ImClone Systems, Inc., a biopharmaceutical company focused on advancing oncology care that was acquired by Eli Lilly and Company in 2008. Additionally, Dr. Rowinsky served as Executive Vice President of ImClone from 2007 to 2009 and Senior Vice President from 2005 to 2007.
His responsibilities at ImClone included managing clinical development, medical affairs, regulatory affairs and corporate strategy. Dr. Rowinsky currently serves as a member of the boards of directors of Biogen Idec Inc., a global biotechnology company, Navidea Corporation, a biomedical company focused on oncology surgical and diagnostic products, Coronado Biosciences, a biopharmaceutical company involved in the development of novel immunotherapy treatments and, from 2007 to 2008, served as a Director of Tapestry Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of cancer therapies.
Since January 2012, Dr. Rowinsky is the Executive Vice-President, Chief Medical Officer and Head of Research and Development at Stemline Therapeutics, Inc. He held the position of Director of the Institute of Drug Development at the Cancer Therapy and Research Center from 2002 to 2004, served there as the Director of Clinical Research from 1996 to 2002 and held the SBC Endowed Chair for Early Drug Development. From 1996 to 2006, Dr. Rowinsky was also a clinical Professor of Medicine, Division Of Medical Oncology and Hematology, at the University of Texas Health Science Center, San Antonio, Texas, and, from 1988 until 1996, an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Rowinsky served on the Board of Scientific Counselors of the National Cancer Institute from 2004 to 2007. Prior to joining ImClone, he was a longstanding National Cancer Institute principal investigator on U01 anticancer drug development grants and a lead investigator on early developmental studies of many classes of cytotoxic agents and targeted therapeutics, including paclitaxel, docetaxel, irinotecan, vinorelbine, topotecan, erlotinib, gefitinib, panitumumab, temsirolimus and ridaforolimus.
Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs and an associate editor of Cancer Research, Clinical Cancer Research, Annals of Oncology, and several other oncology journals and has published over 295 manuscripts in both the preclinical and clinical research fields. His honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. Dr. Rowinsky received a B.A. degree from New York University and an M.D. degree from the Vanderbilt University School of Medicine. Following his residency in internal medicine, Dr. Rowinsky completed fellowship training in medical oncology at the Johns Hopkins University School of Medicine.
Dr. Eric Rowinsky's Press and Information Links:
